Fenwick & West represented Samsara BioCapital in the transaction. Alumis Inc. announced an upsized $259M Series C financing round co-led by existing investor, Foresite Capital, and new...
Alumis’ $259 Million Series C Financing Round
Novartis AG’s Acquisition of Chinook Therapeutics
Fenwick & West LLP represented Chinook Therapeutics, Inc. on the transaction, while Hogan Lovells US LLP represented Novartis AG. Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company, announced...
Morphic Therapeutic’s $276 Million Public Offering
Fenwick represented Morphic Holding, Inc. on the deal. Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment...
Abdera’s $142 Million Financing
Fenwick represented Abdera Therapeutics on the deal. Abdera Therapeutics, a biopharmaceutical company leveraging its advanced antibody engineering ROVEr™ platform to design and develop tunable, precision radiopharmaceuticals...
Third Harmonic Bio’s $213.1 Million IPO
Fenwick represented Third Harmonic Bio, Inc. on the deal. Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company developing a potent, highly selective, oral KIT...
Sanofi’s Pending Acquisition of Amunix
Fenwick & West advised Amunix on the deal, while Weil, Gotshal & Manges advised Sanofi. Amunix, an immuno-oncology company, announced its pending acquisition by Sanofi, a global...
Vanqua Bio’s $85 Million Series B Financing
Fenwick & West advised Vanqua Bio on the deal. Vanqua Bio, a biopharmaceutical company dedicated to discovering and developing next-generation medicines for neurodegenerative diseases, announced its $85...
Lycia Therapeutics’ $70 Million Series B Financing
Wilson Sonsini Goodrich & Rosati advised RTW Investments on the deal while Fenwick & West represented Lycia Therapeutics. Lycia Therapeutics, Inc., a leader in extracellular protein...
T-knife Therapeutics’ $110 Million Series B Financing
Fenwick & West advised T-knife Therapeutics on the deal. Torys LLP acted as counsel to Sixty Degree Capital. T-knife Therapeutics, Inc., a next-generation T-cell receptor company...